Treatment Comparison with Survival and Non-survival Primary Endpoints by Xu, Shuo




A thesis submitted to The Johns Hopkins University in conformity with the
requirements for the degree of Master of Science.
Baltimore, Maryland
May, 2014
c  Shuo Xu 2014
All rights reserved
Abstract
Multiple biomarkers (surrogate endpoints) are often used to predict the failure
event, as well as to evaluate the e↵ect of treatment. In biomarker researches, Behrens-
Fisher problem is a nonparametric two sample comparison problem, which is vital
due to its generality. In this thesis, we proposed a new testing method for Behrens-
Fisher problem. Our method dealt with multiple primary endpoints and focused on
the global e↵ect of a treatment rather than e↵ect for every single endpoints, which
separated us from most of the current studies. We reviewed existing methods dealing
with multiple endpoints Behrens-Fisher Problem with complete data, and introduced
basic characteristics and testing methods for survival data. In light of the limited
ability to process censoring data with current methods, we created this new method
combining information of non-survival markers and survival time to improve accuracy
of the evaluation. Inspired by the idea of rank sum test or U statistics, we built an
adjusted U-statistic to perform the hypothesis test for general two sample comparison
problems. This test o↵ered a reasonable approach to evaluate treatment e↵ect and
inform clinical decision-making when the length of follow-up is available and the
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importance of the primary endpoints could be of equal-weight. In addition, the result
of simulation indicated that our new test would have satisfactory performance under
di↵erent real-world scenarios.
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Survival analysis is a critical component in biostatistics and biomedical research.
But in many circumstances, the process of observing the failure events takes very long
time, so we sometimes prefer to use one or more biomarker(s), which can predict the
real endpoint, as the endpoint(s) instead of the real one, called surrogate endpoint(s).
As surrogate endpoints, the biomarkers must reflect the real endpoint well. There are
many researches in this area, generally Fleming and DeMets[1] have introduced some
rules of choosing surrogate endpoints, such as, when we consider if a new treatment
improves the surviving, the biomarkers we choose must be in the same biological
pathway of how this treatment changes the surviving. As an example, in AIDS
research, we usually use CD4 count as the surrogate endpoint instead of the real
endpoint “developing AIDS”. Fleming and DeMets[1] also mentioned several failures
of trials because of bad surrogate endpoints.
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Traditionally, the researchers used single surrogate endpoint. However, in many
cases, single endpoint is not su cient to address the sceintific question. As the
requirements we need for valid surrogate endpoints, how to choose the endpoints
became the most important question we are facing. Firstly, the true marker, maybe
the first change in the body when a person is developing a disease, sometimes is not
clinically observable or examinable. Such as many neuro diseases like Alzheimer’s
Disease, the change of amount reduction of neurons is not detectable before dissection.
In this case, we can only use the measurable biomarkers as endpoints. And from this
point of view, since any of them are not the true marker, or we say, there is not a
single biomarker can predict 100 percent or near 100 percent sure of the failure event
happening. For example, Huang et al.[2] suggested, Parkinson’s disease disability
was not able to be captured by a single outcome since it had many totally di↵erent
aspects. Secondly, since there is not always a perfect marker for the failure as we
stated before, if we would like to pick only one biomarker as the surrogate endpoints,
there may be di↵erent biomarkers each has its advantages and disadvantages. Then
there comes the realistic problem of consensus among investigators, di↵erent people
may have di↵erent ideas and there is no right or wrong. Finally, since any single
biomarker cannot capture the whole picture, we need more than one biomarkers to
ensure the robustness. From all above, multiple endpoints are needed to capture the
whole spectrum of prediction.
When we compare two treatment groups A and B, using multiple primary end-
2
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points, it is often di cult to correctly assume the joint distributions for these end-
points, a better way is to do a nonparametric test. In most of the researches currently,
the null hypothesis of the two sample test are
H0 : F1 = F2
Where F1 and F2 are the underlying cumulative distribution functions of treatments
A and B. That is, they assume the underlying distributions of the two groups are
the same under the null hypothesis. But in the real world, the di↵erence between
di↵erent treatments will not be only a shift. In many cases, the biological pathways
are even totally di↵erent between the two treatments, so we cannot assume the only
thing changed is the mean value, there will probabily be many other changes that
we do not care and will change the shape of the distribution. At this time, assuming
that we only care about the mean value of the biomarker measurements rather than
the whole shape, the null hypothesis above is not proper. This kind of problem is
called Behrens-Fisher Problem[3], which means a general nonparametric problem of
comparing two groups, without the assumption for the shapes of their distributions.
For this problem, Brunner et al[4] raised a format of Hypothesis as below
H0 : p = P (X < Y ) +
1
2
P (X = Y ) =
1
2
where X, Y are the endpoint measurement random variables for subjects from groups




H0 : ✓ = 0
This format o↵ers a very good intuition and a big flexibility, and will fit more general
questions[5, 6].
On the other hand, in the multiple endpoints problem, there is a general question
must be asked, that is, what is the decision strategy, or how do we decide when
the influence of the two treatments on di↵erent endpoints are di↵erent. Because it
is almost impossible that one method beats the other one on each of the endpoints
we measured, the decision is not obvious when the two treatments both have its
better parts. In many cases, for example in Parkinson’s disease’s treatments, it has
many di↵erent important aspects that we cannot say that there is one aspect that is
important and another one is not. Under this condition, Huang et al.[2] raised a new
format of hypothesis that put equal weight on all of K biomarkers, that is,




















are the random variables of the
vth biomarker measuments for subjects from groups A and B. This setting makes an
easy and reasonable decision making strategy by looking at the global e↵ect, when
we have multiple endpoints with equal importance.
In most of trials focusing on biomarkers, as we mentioned before, people were
dealing with biomarkers as surrogate endpoints or predictions for the true failure,
instead of using the true failure. But there are many cases that we could also observe
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some true failure. In this situation, it is very helpful if we could add the real failure
time into consideration. On the other hand, “failure event” can be encountered
in di↵erent scenarios For example the initiation of levodopa is a failure event in
Parkinson disease progression. Motor Function scores can be masked by the use of
levodopa. Since the di↵erent patients have di↵erent levodopa initiation times, the
follow up time will be di↵erent if we compare motor function score. Therefore, if we
just measure the biomarkers without considering the followup time, the results may
be biased. So we would like to add the real failure as another endpoint among the
biomarkers and see the whole picture. But when we are discussing survival data, we
must deal with censoring. In this work, we will also discuss the methods dealing with
Behrens-Fisher Problem with censored data, and try to combine all the endpoints




2.1 Current Research with Complete Data
As we are considering Behrens-Fisher Problem, we do not care the shapes of
the underlying distributions, we set our null hypothesis only about the mean. For
convenience, we assume that for each outcome, the larger value is preferred[7]. If









j1, ..., Yjk) be the k outcomes from subject j(j = 1, 2, ..., n) in group B.
Suppose the X
i
’s are independent and identically distributed, with joint cumulative
distribution function F , and the Y
j
’s are independent and identically distributed,
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with joint cumulative distribution function G. The null hypothesis is set as below [2]:





















) , the null hypothesis can be written as following [2]:
H0 : ✓1... = ✓k = 0.
2.1.1 O’Brien’s Test
Under nonparametric assumption, we usually use the rank or rank sum to get
information and to test if two groups have the same mean. If we consider the multiple
biomarkers case, assuming we have k biomarkers, we are able to get ranks for each
of the biomarkers. For the vth outcome, we combine the two groups together and
the m+ n subjects X1v, ..., Xmv, Yiv, ..., Ynv, and then a unique rank will be assigned
to each subject. Then the ranks are seperated into two groups with respect to the








), if we havs tied
data, the rank of the tied subjucts will defined as the average of their ranks. The





v=1 Rx,iv, similarly for the






Consider equal variance case, O’Brien[8] performed a test as a regular two-sample
t-test for two rank-sum samples: R
x1, ..., Rxm and Ry1, ..., Ryn, with the standard
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2.1.2 Adjusting of O’Brien’s Test
The O’Brien’s test is very widely used in clinical trails since it is simple in format
and easy to calculate, but when we go back to our assumptions of the problem as a
Behrens-Fisher Problem, this test actually has a big problem such as it is not always
correct when people use it.
In the paper of Huang et al.[7], they proved that assuming m/n !   as N =
m+n ! 1 for some finite constant  , under the null hypothesis, as N goes to infinity,
the O’Brien’s test statistic T2 converges in distribution to a normal distribution with






































































































(t) = P (X
u
< t) + 12P (Xu = t), G
o
u
(t) = P (Y
u
< t) + 12P (Yu = t), are the
mid-distribution function for the uth outcome (u = 1, 2, ..., k).
Consider the underlying distributions of two groups, which are F and G, we notice
that the null hypothesis does not imply F = G. When the null hypothesis is true
but F and G are di↵erent, the h1 will not equal to 1, which ruins the statement
that the O’Brien’s test statistic T1 follows the t distribution. Therefore, the type I
error will not be controlled if we use O’Brien’s test when we have unequal underlying
distribution.
Under this circumstance, Huang et al.[7] has proposed a method to adjust the











And the simulations by Huang et al.[7] showed a good performance of the adjusted
statistic.
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2.2 Introductions of Characteristics of Sur-
vival Data
Survival analysis is one of the major branches in biostatistics, and it is unique and
very important due to the special characteristics of survival time random variables.
It deals with the analysis of the time to a failure event, called failure time or survival
time. This failure event is the event we set as an endpoint, such as death, diagnosis of
disease, or hospitalization, it can be either repeatable or not. In survival analysis, the
interest of research is usually the surival function and hazard function. The survival
function is defined by,
S(t) = P (T   t),
where T is the survival time from the time origin to the failure event, it is a non-
negative random variable, and t is any timepoint. When T is a continuous random
variable, we have S(t) = 1  F (t). And hazard function is defined by
 (t) = P (T = t|T   t) (if T is discrete),
= lim
 !0+
P (t  T < t+ |T   t)
 
(if T is continuous),
which has the property of  (t) = f(t)/S(t). When T is continuous, the harcard
function is the instantaneous failure rate at t given survival until t. Here f(t) is the
probability density function of T and F (t) is the cumulative density function of T . In
many cases, for example when T follows exponential distribution, the hazard function
10
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and the survival function will have very simple expressions which make good sence
for interpretation and for real world cases.
The uniqueness of surival analysis is that it comes with unique formats of missing
data. The most common format of missing data is called right-censoring, which
means we lose followup of some subject at a time point. Censoring can due to many
reasones, such as subjuect’s withdrawal, death due to other reasons, or the end of the
study (administrative censoring). In most cases, we assume the censoring time C is
independent of failure time T .
In real study, the observed time is X = min(T,C), paired with binary censoring
indicator  . The censoring indicator equals to 1 when the subject is not censored,
eqauls to 0 otherwise. Because of censoring, we cannot estimate the survival function
of the failure time with the methods dealing with complete data. A widely used
estimator for survival function is Kaplan-Meier Estimator[10], and it will deduce to
empirical distribution when there is no censoring. For two-sample testing, we usually
perform log-rank test and Gehan’s test. In our work, Gehan’s approach will be applied
on our test statistics, and detailed discussion will be presented in the following section.
11
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2.3 Test With both Usual Biomarkers and
Survival Time
Since it is very hard to estimate the joint distribution of di↵erent biomarkers and
survival time. Instead of estimating the joint distribution directly, we focus on the
distribution of their ranks alternatively. There are a lot of studies dealing with multi-
ple biomarkers, but almost none of them includes survival time information. Here we
use U-statistics, a kind of unbiased statistic, to combine all the information together.
All the biomarkers and survival time are coded as the larger value is preferred. Also
we assume that independent censoring in our case.
Using the similar notions with in section 2.1. Assume we have K biomarkers and
we also care about the survival time. Let X
i
= (X
i1, ..., XiK , Xi,K+1,  Ai) be the ob-
servation from subject i (i=1,2,..,m) in group A, and Y
j
= (Y
j1, ..., YjK , Yj,K+1,  Bj)be




, v = 1, 2, ..., K
is the measurements for one subject of the vth biomarker. X
i,K+1 or Yj,K+1 is the
survival time observation with X
i,K+1 = min(TAi, CAi) and Yj,K+1 = min(TBj, CBj),





indicator. Denote G1, G2 are the “survival function” of the censoring time C1, C2.
We are testing the hypothesis as below:





/(K + 1) = 0
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v.s.
H1 : ✓ 6= 0,










), v = 1, 2, ..., K + 1.
Consider the vth non-survival outcome, we rank all the subjects in both groups
together and assume the rank sum of group A is R
Av
, by the results of Mann-Whitney,
R
Av





















































Under the null hypothesis, U
v
will follow a Normal distribution with mean 0 and
variance calculable. Here, for each variable, the di↵erence between the rank sum of
group A and the corresponding U-statistic is a constant as the group sizes for both
group are fixed. Therefore, we could build the statistics using the U-statistics, instead
of the original rank sum, and get the same result. On the other point of view, the
13
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definition of this statistic give us a good “description” on how to estimate the ✓ in



















Similarly, for the survival outcome, we would like to use the same statistic to build
a link to the rank-sum of a specific group or the value of ✓ which we care the most.
So here, for combining the multiple endpoints, we would like to add all the rank
sums together. Also we adjust the statistic with the sample size to make it a good












((K + 1)mn) .
As all these U-statistics are following normal distributions, so the adjusted sum U
sum
will still follow the normal distribution with mean 0 and calculable standard error.





’s because of censoring, as we mentioned earlier in this work. So we need to
estimate the U
K+1. There are two approaches we can use here, the first one is to












ij,K+1 = 1 if TAi > TBj,
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Û
ij,K+1 = 0 if TAi = TBj, or unknown
Û
ij,K+1 =  1 if TAi < TBj .
i.e.
Û
ij,K+1 = I(TAi > TBj)  I(TAi < TBj)
For the alternative approach, we use the method introduced in Cheng, Wei, and















Where Ĝ1 and Ĝ2 is the estimated survival function for censoring, using Kaplan-Meier





we can also estimate the corresponding statistic U








   AiI(Xi,K+1 < Yj,K+1)
Ĝ1(Xi,K+1)Ĝ2(Xi,K+1)
.
























Until now, we have obtained all the U-Statistics for biomakers and estimated
the U-statistic for the survival time variable using two di↵erent approaches. we can












((K + 1)mn) .
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Under the null-hypothesis, the theoretical mean of Û
sum
is 0, and we will use
bootstrap to estimate the variance in each specific case when we have real data.
Further more, we still would like to consider the theoretical value of the variance






























Here !(.) is a weight function, when we set it !(.) = 1 we get W
K+1 = ÛK+1. In
paper of Huang et al.[4], they proved, with some trivial assumptions, under the null-
hypothesis, the vector (W1, ...,WK) converges to a multivariate normal distribution





























and here, she assumed that {(X
i1, ..., XiK), i = 1, ...,m} and {(Yj1, ..., YjK), j =
1, ..., n} are independent identically distributed realizations of the random vectors
(X
.1, ..., X.K) and (Y.1, ..., Y.K); F1u(t) = P (X.u < t)+P (X.u = t), F2v(t) = P (Y .v <
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t) + P (Y .v = t); and ⇠(x, y) = I(x > y)  I(x < y). And the estimation method for





To evaluate the performance of the test we described above, we simulate the
original data from di↵erent distributions. Assume both group have 100 individuals,
and there are K biomarkers, K = 3. Also, assume that the length of the study period,
which is the maximum possible value of censoring time, is 3 years. For the population
we generated, we use Normal distribution and Beta to generate the biomarkers data,
exponential distribution to generate the true survival time. Also, we consider the
correlation between the covariates, as well as generate the simplest case that all the
covariates are independent. For censoring time, we generate it from an independent
uniform distribution along the study period, regarding the independent censoring
assumption.
18
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Each time after generating a set of data, we use both of the two approaches we
mentioned in the last section to obtain the statistic Û
sum
’s on the same data. We use
bootstrap to estimate the standard deviation and 95% confidence interval. At the
same time, for each distributions we use to generate data, we will generate 500 sets
of data, with each we calculate the variance and confidence interval of the statistics
Û
sum
’s, to explore or compare the properties of the variance by the two methods, also
for the cases under the null hypothesis H0 we check the Type I errors and for cases
under alternative hypothesis H1 we check the powers of the test.
Here we consider 3 pairs of settings of the true underlying distribution of the end-
points and we evaluate the performance of the two approaches of test under each of
the settings. In each pair, we have one settings under the null hypothesis and one
under the alternative hypothesis. And the two settings in the same pair has the same
type of distrubution for each of the biomarkers, but they will have di↵erent mean
vector. In the three cases under althernative hypothesis, we also perform a Bonfer-
roni test (denoted by Approach 3 in the summary table) to compare the power and
type I error of the tests. Here are the 3 pair of cases, denoted by case 1-3,
Case 1 Biomarkers data from groups A and B follows multivariate normal distribu-
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Survival time for groups A and B are generated from exponential distributionsExp( 1),
Exp( 2). The censoring time for each subject from each group are following the
Uniform distribution on the interval [0, 3]. For the under null hypothesis setting,
µ1 = µ2 = (0, 0, 0),  1 =  2 = 0.5. For the under althernative hypothesis setting,
µ1 = (0, 1, 2), µ2 = (0, 1.2, 2.5),  1 = 0.5,  2 = 0.4.
Case 2: In groups A and B, biomarkers data follows multivariate normal distribution,










The survival time for each subject from each groups A and B are generated from ex-
ponentials distribution Exp( 1), Exp( 2) plus 0.03 times of the value of measurement



















The censoring time for both group are following the Uniform distribution on the
interval [0, 3]. For the under null hypothesis setting, µ1 = µ2 = (0, 0, 0),  1 =  2 =
0.5. For the under althernative hypothesis setting, µ1 = (0, 1, 2), µ2 = ( 1, 3, 2.5),
 1 = 0.5,  2 = 0.4.
Case 3: In group A, biomarkers follow multivariate normal distribution, with mean
20
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µ1 and covariance matrix ⌃3, where ⌃3 is same defined as in case 2. In group B,
the data of 3 biomarkers are following Beta distributions Beta(0.7, 1), Beta(0.5, 1),
Beta(2, 4), correspondingly, plus a shared error ✏, where ✏ follows normal distribution




j1 + ✏, Y
0




j2 + ✏, Y
0




j3 + ✏, Y
0
j3 ⇠ Beta(2, 4)
✏ ⇠ N(0, 0.052)
. Survival time for each subject from groups A and B are generated, from from
exponential distributions Exp( 1), Exp( 2) plus 0.03 times of the value of mea-
surement of the first biomarker. The censoring time for both group are following
the Uniform distribution on the interval [0, 3]. For the under null hypothesis set-
ting, µ1 = (0.41, 0.33, 0.33), according to the mean of Beta distributions in group
B,  1 =  2 = 0.5. For the under althernative hypothesis setting, µ1 = ( 0.5, 0, 0),
 1 = 0.5,  2 = 0.4.
In case 1, 2, we run the bon↵eroni test by Wilcoxon’s rank sum test for biomarkers
and Gehan’s test with bootstrap with survival time. In case 3, since the underlying
distributions of biomarkers in two groups have di↵erent shapes, it will be biased if
we still use Wilcoxon’s rank sum test without adjusting, then here we use bootstrap
21
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methods to perform the Bon↵eroni test. The simulation results are shown in the table
3.1.
From the simulation results, we can see both the two approaches perform well in
di↵erent kinds of underlying distribution settings. On average, the first approach has
a slightly smaller variance than the second approach. They both o↵er a good contor-
lled Type I error around 0.05, especially Approach 2. For the power term, Approach
2 has a slightly lower power than Approach 1, which may be improved if we adjust
for the Kaplan-Meier estimator before we calculate the test statistic in Approach 2.
Compared with Bon↵eroni test, Although the Bon↵eroni test sometimes has a incred-
itable high power, we need to notice that what we are testing is the global e↵ects.
Observing the case settings, it is easy to see that two groups may have big di↵erence
for one sigle biomarker, but the data is coded as that “di↵erence between the groups”
may have di↵erent directions, or significant di↵erence for only one biomarker will not
be that significant averagely for the whole picture. In this situation, the high power of
Bon↵eroni test will not be meaningful. On the other hand,our new approaches make
more sense in the setting of the global wised null hypothesis. Because, for a beferroni
test, the null hypothesis is usually “each biomarkers has same mean bewteen the two
groups”, instead of our global setting. Therefore, our new apporach is better fitted in
the goobal testing problem. And this results indicated that the performance of the
test have not been influenced by the shape of the underlying distribution, that means
when we are not able to specify the same kind of distribution or same shape between
22
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Table 3.1: simulation summary.




) Type I error Power
H0 1 1 0.00137 0.0378 0.038
2 0.00157 0.0437 0.038
3 0.038
H1 1 -0.0962 0.0375 72.2%
2 -0.0967 0.0427 63.8%
3 81.6%
H0 2 1 0.000851 0.0442 0.060
2 0.000974 0.0496 0.046
3 0.054
H1 1 -0.212 0.0371 68%
2 -0.212 0.0421 61.6%
3 100%
H0 3 1 -0.00114 0.0485 0.054
2 -0.00158 0.0532 0.052
3 0.050
H1 1 -0.179 0.0467 96.6%
2 -0.179 0.0510 94.3%
3 98.6%
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the variables in the two groups, it is a very good test to justify which treatment has
the high expectation value.
In the above simulation, we assumed that the distributions of the censoring time
are the same between the two groups. When the censoring distributions are di↵erent
between two groups, we can not use the approach 1 because of the model assumption
reqiurement for Gehan’s Method of estimating the U statistic. But this unequal cen-
soring case is also a general problem in the real studies. So for the same distribution
types on biomarkers and survival times as in case 3, we just change the censoring
distribution of group B to be exponential distribution Exp(0.5) bounded by [0, 3], to
gain the two new settings denoted as case 4. In case 4, for the under null hypoth-
esis setting, µ1 = (0.41, 0.33, 0.33), according to the mean of Beta distributions in
group B,  1 =  2 = 0.5. For the under althernative hypothesis setting, µ1 = (0, 0, 0),
 1 = 0.5,  2 = 0.4. In case 4, Under this two setting we run the simulation to check
the perform of the second approach and we got table 3.2. Notice that here we use
bootstrap method for biomarkers and the same mathod with Approach 2 for survival
times when we run the Bon↵eroni test.
Comparing table 3.2 with table 3.1, we find that this test also performs well in the
unequal censoring conditions. Despite that the Bon↵eroni test will produce incorrect
high power, when for each single biomarker the di↵erence is samll but there is a
significant global di↵erence, as the setting in case 4, the power of Bon↵eroni test also
will go low, but in this situation our new approach has sensitively detected the global
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Table 3.2: simulation summary for unequal censoring cases.




) Type I error Power
H0 4 2 -0.00749 0.0531 0.060
H0 3 0.054
H1 2 -0.129 0.0519 68%
H1 3 53.6%
di↵erence. But when we run it for many times we will find that sometimes the type
I error will be be controlled as well as the same censoring distribution cases. This
may be caused to the unadjustment of the estimated survival function for censoring
time for each distribution. In this test, we just plug in the Kaplan-Meier estimator
without adjusting, which may cause bias of estimating U
K+1 in certain cases. For
example, the value of Kaplan-Meier estimator may be very small on the tails of the
curve, which will cause large variance when we calculate the Û
K+1. In the future, we
will do the adjustment for Kaplan-Meier estimator to improve the performance of our
testing method.
3.2 Example
To mimic the real data, we generate three sets of data from case 3, 4 mentioned
in the simulation section, with sample size equals to 200 in each group and numbers
of endpoints K + 1 = 4. Treat them as the original data we have, we perform the
25
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test based in these data.
3.2.1 Example 1
Firstly we generate a set of data with setting case 3 under null hypothesis, sample
size m = n = 200 and number of endpoints K + 1 = 4. We first use histograms to
explore the basic characteristics of the data we have for both groups (Figure 3.1 and
Figure 3.2). From the histograms we could see that the distrbution shapes of each
biomarkers are di↵erent from the two groups, but they will have the about the same
mean.
Then we perform the test by both of the approaches, and Table 3.3 shows the
results we got from the two approach. From here we can see, the results from the two
approaches are very similar and the first approach has a slightly smaller variance and
slightly smaller di↵erence with the theoretical mean. But on the whole the two tests
performs both very well here.





) 95% C.I.for Û
sum
Decision
Approach 1 -0.0260 0.0345 [-0.0959, 0.0337] Fail to reject
Approach 2 -0.0325 0.0378 [-0.110, 0.0382] Fail to reject
Also we plot the histogram of Û
sum
’s (Figure 3.3) by the two approaches and we
can see it estimated the value of ✓ well.
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Figure 3.1: Example 1: data distribution of group A (histograms).
3.2.2 Example 2
For the second example we generate a set of data with setting case 3 with al-
thernative hypothesis, sample size m = n = 200, µ1 = (0, 0, 0) and and number of
endpoints K + 1 = 4. Similarly, we use histograms (Figure 3.4 and Figure 3.5) to
explore the basic characteristics of the data we have for both groups. Notice that the
underlying distribution is under the alternative hypothesis.
We perform the test by both of the approaches, the summary of results we got
27



























































Figure 3.2: Example 1: data distribution of group B (histograms).
from the two approach is listed in Table 3.4. At the same time we have the histogram
of Û
sum
(Figure 3.6). From here we can see, the results from the two approaches are
still very similar and the first approach has a slightly smaller variance. Both the two
tests performs both very well here. And from Figure 3.6, we can find the Û
sum
’s from
both of approaches has estimated the value of ✓ well.
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Finally we generate a set of data with setting case 4 with alternative hypothesis,
sample size m = n = 200 and number of endpoints K+1 = 4. The histograms of the
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Figure 3.4: Example 2: data distrubution of group A (histogram).





) 95% C.I.for Û
sum
Decision
Approach 1 -0.138 0.0327 [-0.202, -0.0756] Reject
Approach 2 -0.144 0.0376 [-0.218, -0.0631] Reject
four endpoints for both groups is shown in Figure 3.7 and Figure 3.8. Notice that the
in this setting alternative hypothesis is true.
As we mentioned before, in this unequal consering condition, we can only use the
second approach. We list the reault of the test on this data in Table 3.5 and histogram
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Table 3.5: Example 3: Testing results.
Approach Û SD(Û
sum
) 95% C.I.for Û
sum
Decision
Approach 2 -0.144 0.0347 [-0.212, -0.0673] Reject
From the plotting (Figure 3.9) we could see the estimation of U
sum
’s by each time
of the bootstrap process are well normally distributed, and by the result summary
we could see this method works well in this example case and the estimated variance
term of the estimated U, or we say the estimation of ✓ is fairly well.
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Figure 3.7: Example 3: data distrubution of group A (histogram).
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Figure 3.8: Example 3: data distrubution of group B (histogram).
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The rank sum test for multiple endpoints showed a very practical way to deal with
Behrens-Fisher Problem and is already widely used in clinical trials research. Now
we put survival time into the test methods, o↵ers a good method to make better use
of the survival information we have and will definitely increase the accuracy of the
comparison.
The big advantage of this method is that, as we mentioned in both method and
simulation sections, it is non-parametric and can deal with the two sample problems
without assuming the same underlying assumptions, which will fit more general prob-
lems. Also, di↵erent from many traditional tests, we do not assume that between the
two groups the directions of changes of each biomarker are all the same, which means
we do not require one group beating or being not worse than the other on every
aspects before we say this treatment is better. Instead, this method o↵ers a way to
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evaluate a treatment globally on a whole picture.
From the simulation section, we could see that in di↵erent conditions or assump-
tions, we can get the correct decisions by performing this test using bootstrap at
most of time. From both approaches of test, we can ensure a high power and low
Type-I-error. But, the correlation we assumed in the simulation part is very simple,
the real case will be more complicated. We still need to put more e↵ort on how to
mimic the correlation in the real data, as the correlation between biomarkers and
between biomarker and survival time has a lot of di↵erent formats.
For the first approach, we use the Gehan’s Method of estimating the U statis-
tics, which requires the equal censoring distribution for both groups. This gives this
method a big limitation when we try to use it in a real study. In many cases, we
will have informative censoring, or the censoring time may depend on di↵erent not
medical related condition, which may lead to a di↵erence between the censoring dis-
tribution of the two groups. From this viewpoint, the second approach will be more
general and requires less assumptions.
At the same time, the developing of the theoretical expression of our new statistic
and its property is going to be completed in the close future. Also, as mentioned
in simulation section, work still need to be done to adjusting for the Kaplan-Meier
estimator for approach 2, will may be able to o↵er a better performance of this
approach.
At this point, we see advantages and feasibility of this new testing method. This
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method o↵ers a good way to solve the problem of the lack of analysis for survival
time in biomarkers research and a way to make more sense in treatment comparison
in many real situations by evaluating global e↵ects . We have reasons to believe that
our new approaches will be useful and have a good performance on real data, and we




A.1 Bootstrap Function for Approach 1








sam1<-sample(num1, size=n1, replace = TRUE, prob = NULL)























return(c(mean(U),sd(U),quantile(U, probs = c(0.025,0.975),na.rm=T),
quantile(Us, probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)))
}










APPENDIX A. R CODE
sam1<-sample(num1, size=n1, replace = TRUE, prob = NULL)
























ci1<-quantile(UB[,1], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
ci2<-quantile(UB[,2], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
ci3<-quantile(UB[,3], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
ci4<-quantile(UB[,4], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
rej<-(ci1[1]>0|ci1[2]<0)|(ci2[1]>0|ci2[2]<0)|(ci3[1]>0|ci3[2]<0)|
(ci4[1]>0|ci4[2]<0)
return(c(mean(U),sd(U),quantile(U, probs = c(0.025,0.975),na.rm=T),rej))
}
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A.3 Bootstrap Function for Approach 2
Bootstrap2<-function(data10,data20,X10,X20,ind10,ind20,n1,n2,N,K){
U<-rep(0,500)




sam1<-sample(num1, size=n1, replace = TRUE, prob = NULL)
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quantile(U, probs = c(0.025,0.975),na.rm=T)))
}
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sam1<-sample(num1, size=n1, replace = TRUE, prob = NULL)
































































ci1<-quantile(UB[,1], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
ci2<-quantile(UB[,2], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)
ci3<-quantile(UB[,3], probs = c(0.025/(K+1),1-0.025/(K+1)),na.rm=T)




quantile(U, probs = c(0.025,0.975),na.rm=T),rej))
}
A.6 Data generating and test evaluation
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for (LOOP in 1:500)
{
#data
































[1] T. R. Fleming, and D. L. DeMets. (1996). Surrogate end points in clinical trials:
Are we being misled? Ann Intern Med 125, 605-613.
[2] P. Huang, R. F. Woolson and P. C. OBrien. (2008). A rank-based sample size
method for multiple outcomes in clinical trials, Statistics in Medicine 27, 3084-
3104.
[3] R. A. Fisher. (1996). The fiducial argument in statistical inference, Annals of
Eugenics 6, 391398.
[4] E. Brunner, U. Munzel, and M. L. Puri. (2002). The multivariate nonparametric
BehrensFisher problem, Journal of Statistical Planning and Inference 108, 37-53.
[5] P. C. O’Brien, N. L. Geller. (1997). Interpreting tests for e cacy in clinical trials
with multiple endpoints, Controlled Clinical Trials 18, 591-602222-227.
[6] L. Acion, J. J. Peterson, S. Temple, S. Arndt. (2006). Probabilistic index: an intu-
49
BIBLIOGRAPHY
itive non-parametric approach to measuring the size of treatment e↵ects, Statistics
in Medicine 25, 591-602.
[7] P. Huang, B. C. Tilley, R. F. Woolson, and S. Lipsitz. (2005). Adjusting O’Brien’s
test to control Type I error for the generalized nonparametric Behrens-Fisher prob-
lem. Biometrics 61, 532-539.
[8] P. C. O’Brien. (1984). Procedures for comparing samples with multiple end-
points. Biometrics 40, 1079-1087.
[9] S. C. Cheng, L. J. Wei, and Z. Ying. (1995). Analysis of Transformation models
with censored data, Biometrika 82, 835-845
[10] E. L. Kaplan, and P. Meier. (1958). Nonparametric estimation from incomplete
observations, JASA 53, 457-481
50
Vita
Shuo Xu received the B.S. degree in mathematics
and applied mathematics from Nanjing University in
2012, enrolled in the Biostatistics Sc.M. program at
Johns Hopkins University in 2012, and has been an ex-
change student in National Tsing-Hua University (Tai-
wan) in 2010. She won the Nanjing University Honor
Student in 2009, received a Nanjing University Third
Class People’s Scholarship in 2009 and Johns Hopkins Bloomberg School of Public
Health 75% Master’s Tuition Scholarship in 2013, and was an Outstanding Member
of Nanjing University Red-Cross and an approved first-aid provider for Jiangsu Red-
Cross. Her current research focuses on survival Analysis and surrogate endpoints,
her undergraduate research focused on congruence theory in number theory, and her
co-authored paper with Z. Zhang “Cryptanalysis and Improvement of a Concurrent
Signature, Scheme Based on Identity” was published on The 2nd IEEE International
Conference on Software Engineering and Service Sciences (2011 Beijing, China).
51
VITA
52
